Therefore, an engineered and recombined leptin dose [209], leptin receptor agonists, and leptin sensitisers [210] have been developed to reduce this phenomenon and make more effective leptin molecules across the blood–brain barrier to reach its effective site to treat obesity and obesity-related CVD [208], typically for treating premenopausal obese females. The gene discussed is LEPR; the disease is obesity due to melanocortin 4 receptor deficiency.